Generate Biomedicines, Inc.
No enriched coverage for $GENB in the last 7 days.
No SEC Form 4 filings for $GENB in the last 30 days.
See all $GENB insider activity →Generate Biomedicines (GENB) dosed the first patient in a Phase 1 trial for GB-5267, an AI-designed CAR T therapy targeting ovarian cancer. The trial marks the company's entry into solid tumor treatments. Investors await safety and efficacy data for further insights.
Roswell Park and Generate Biomedicines (NASDAQ: GENB) announced the first patient has been dosed in a phase 1 clinical trial for GB-5267, an AI-engineered CAR T-cell therapy targeting MUC16 in ovarian cancer. The trial aims to evaluate the safety and tolerability of GB-5267, which is designed to avoid pre-infusion chemotherapy and its side effects. GB-5267 targets a biomarker over-expressed in over 80% of ovarian tumors, aiming to optimize T-cell function in solid tumors.
Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
Recent GENB coverage spans financial news, earnings and market movers.
The trial start introduces a new clinical‑stage catalyst for GENB; short‑term price impact is limited, but positive data could drive upside.
The trial start introduces a new clinical milestone for Generate, potentially increasing speculative interest but also adding execution risk.
Loss widening and trial updates may pressure short term but long‑term upside from Phase 3 data.
Quarterly earnings miss and cash runway extension may pressure the stock despite trial progress.
Clinical execution and cash runway updates are the key tradable elements, with near-term catalysts tied to ERS/ESMO poster presentations and ongoing enrollment.
AlphAI scores every news story that mentions GENB with an AI model for sentiment and relevance, and aggregates insider trades from Generate Biomedicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Generate Biomedicines (GENB) dosed the first patient in a Phase 1 trial for GB-5267, an AI-designed CAR T therapy targeting ovarian cancer. The trial marks the company's entry into solid tumor treatments. Investors await safety and efficacy data for further insights.
1 min readRoswell Park and Generate Biomedicines (NASDAQ: GENB) announced the first patient has been dosed in a phase 1 clinical trial for GB-5267, an AI-engineered CAR T-cell therapy targeting MUC16 in ovarian cancer. The trial aims to evaluate the safety and tolerability of GB-5267, which is designed to avoid pre-infusion chemotherapy and its side effects. GB-5267 targets a biomarker over-expressed in over 80% of ovarian tumors, aiming to optimize T-cell function in solid tumors.
2 min readSeveral biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.
3 min readGenerate Biomedicines (GENB) reported Q2 2026 revenue of $6.3M, down from $10.1M YoY, with net loss widening to $67.3M. R&D and G&A expenses rose, driven by Phase 3 asthma trials. Cash reserves total $457.4M. GENB advanced clinical trials for asthma, COPD, and oncology treatments, with Novartis progressing a biologic using its AI platform. Shares rose 19.02%.
2 min readGenerate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase
6 min readNvidia (NVDA) said AI’s “most profound impact” will be in life sciences and announced an AI co-innovation lab with Eli Lilly, targeting up to $1 billion over five years. Nvidia’s May 13F showed it owned 833,000+ shares of Generate Biomedicines (GENB), valued at about $10.4 million as of Q1 end. The article links Nvidia’s AI push to its biotech investment.
7 min readNvidia, through its venture arm NVentures, owns 833,325 shares of Generate Biomedicines (NASDAQ: GENB), according to the article. The stake totals about $13 million, and Generate Biomedicines is a pre-profit biotech developing an AI platform for virtual drug testing; four candidates are in its pipeline, including one in Phase 3 for severe asthma (GB-0895). The piece cites estimates that drug development can take 10–15 years and about $2.6 billion per approved medicine.
6 min readReuters (May 27) reported Biohub, founded by Meta CEO Mark Zuckerberg and Priscilla Chan, developed an open-source global protein-biology model using fourth-generation evolutionary scale modeling (ESM) to speed drug discovery. Biohub said it will run via Biohub.ai and partners like AWS Bio Discovery, with computing credits, and expects broader lab use. The article also lists hedge-fund “AI drug discovery” holdings, including SOPHiA Genetics’ proposed MSK precision-oncology JV and Generate Biomed
6 min read
